Clinical Trial Update: Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update examines linvoseltamab plus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma to deepen responses or dr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Linvoseltamab

Snippet

Sponsor: Dickran Kazandjian, MD | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING